FRASNET Cohort: FGF21 Biomarker and Depressive Symptoms in Older Adults

52 older individuals from the FRASNET cohort underwent longitudinal assessments from 2017 to 2024. The dataset, authored by Sarah Damanti and last updated in 2026, investigates the association between circulating Fibroblast Growth Factor 21 (FGF21) levels and depressive symptoms measured by the Geriatric Depression Scale.

Use Cases

• Predicting depressive symptom trajectories based on baseline biomarker levels mentioned in the description
• Analyzing the longitudinal relationship between a stress-induced hepatokine and mental health outcomes
• Training models for modest discriminatory performance (AUC=0.66) in identifying elevated depressive symptoms
• Conducting hypothesis-generating studies on inflammation and neuroendocrine regulation in depression

Strengths

• Longitudinal data spanning 7 years (2017–2024)
• Clinical measures include Geriatric Depression Scale (GDS) scores and biomarker levels
• Regression models adjusted for age, sex, and body mass index

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• The authors note findings are preliminary, based on a modest sample of 52 individuals

Provenance

Source

Sarah Damanti via figshare

Collection Method

Data obtained from the FRASNET cohort of community-dwelling older adults.

Time Range

2017–2024

Freshness

Last updated 2026 04-10 05:58:47

Geography

null